Vanta Bioscience Ltd

As of August 4, 2025, Vanta Bioscience is considered overvalued and risky due to poor financial ratios, including a PE Ratio of -3.38 and an ROE of -31.38%, alongside a year-to-date stock decline of 42.53%, significantly underperforming its peers and the market.

Vanta Bioscience has shown fluctuating historical performance, with net sales increasing to 9.72 Cr in March 2024 from 6.28 Cr in March 2023, but continues to face profitability challenges, reporting a net loss of -2.32 Cr in March 2024. While there are signs of recovery in sales and operating profit, the company still struggles with overall profitability and cash flow.

Vanta Bioscience will announce its results on August 1, 2025.

Vanta Bioscience has shown fluctuating net sales and profitability, with net sales increasing to 9.72 Cr in March 2024 from 6.28 Cr in March 2023, but still reporting a net loss of -2.32 Cr. The company is experiencing a gradual recovery in sales and operating profit despite ongoing challenges.

Vanta Bioscience has experienced fluctuating net sales, peaking at 14.14 Cr in Mar'20 and declining to 9.72 Cr in Mar'24, with profitability challenges reflected in negative net profits in recent years. Despite growth in total assets and a positive cash flow from operations in Mar'24, the company has faced increasing liabilities and overall declining profitability.

As of 24th July, Vanta Bioscience Ltd has a market capitalization of 20.00 Cr and reported net sales of 3.45 Cr with a net profit loss of 3.92 Cr for the latest quarter ending March 2023. Shareholder's funds are 15.20 Cr, and total assets amount to 85.40 Cr as of March 2024.

Vanta Bioscience's historical performance shows fluctuating net sales, with an increase to 9.72 Cr in March 2024 from 6.28 Cr in March 2023, but it still reported a net loss of -2.32 Cr. Despite improvements in operating profit and margins, the company continues to face challenges with profitability.

The top shareholder of Vanta Bioscience is Mohan Krishna Mulakala, holding 55.22% of the shares. Individual investors own 26.35%, while the highest public shareholder is A Vimalchand with 1.09%.

As of March 2020, the management team of Vanta Bioscience includes Mohan Krishna Mulakala (Chairman), Dopesh Raja Mulakala (Managing Director), Vyasmurti Madhavrao Shingatgeri (Whole-time Director), Padmanabhuni Venkata Appaji (Independent Director), Zoheb Sayani (Company Secretary), Sadhanala Venkata Rao (Whole Time Director & CEO), and Yogeswara Rao Danda (Additional Independent Director). Each member contributes to the company's governance and operations.

Vanta Bioscience's peers include Chennai Meena, Samsrita Labs, Adeshwar Meditex, Family Care, Gian Lifecare, Dr Lalchand. Lab, Looks Health, Dhanvantri Jeev., and Clinitech Lab. Key metrics show varying management risks and growth ratings, with Samsrita Labs having the highest 1-year return at 4.43% and Adeshwar Meditex the lowest at -30.77%, while Vanta Bioscience's return is -48.64%.

As of July 10, 2025, Vanta Bioscience is considered overvalued with a PE ratio of 16.67 and a low ROCE of 5.37%, significantly underperforming the Sensex with a 40.57% decline year-to-date, leading to a shift in its valuation grade from risky to does not qualify.

As of May 21, 2025, Vanta Bioscience's trend is mildly bearish, influenced by daily moving averages and Bollinger Bands, despite some bullish signals from the weekly MACD and monthly RSI.

As of May 21, 2025, Vanta Bioscience's trend is mildly bearish, influenced by daily moving averages and Bollinger Bands, despite some bullish signals from the weekly MACD and monthly RSI.

As of January 2, 2025, Vanta Bioscience is considered undervalued with a PE ratio of 16.92 and an EV to EBITDA ratio of 11.52, despite a low return on equity of 0.25% and a significant stock decline of 51.74% over the past year.

Vanta Bioscience Ltd is a micro-cap company focused on preclinical healthcare services, with recent net sales of 3 Cr and a net profit of -3 Cr as of March 2023. The company has a market cap of Rs 17 Cr and key financial metrics include a P/E ratio of 17.00 and a debt-equity ratio of 1.28.

As of 05-June, Vanta Bioscience Ltd's stock price is at 26.80, reflecting a 1.98% increase. Despite a recent short-term gain of 8.06%, the stock has a concerning year-to-date decline of 39.69%, indicating weaker long-term performance compared to the broader market.